Quick Answer
AYTU BIOPHARMA, INC reported Operating Income Loss of -$7.83 million for the year ending 2025.
- AYTU BIOPHARMA, INC showed a decrease of -392.0% in Operating Income Loss from 2024 to 2025.
- This data is from AYTU BIOPHARMA, INC's annual report (Form 10-K), filed with the SEC on September 23, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), AYTU BIOPHARMA, INC's Operating Income Loss has declined by 5,757.7%.
- Historical annual values: Fiscal year 2025: -$7.83 million | Fiscal year 2024: -$1.59 million | Fiscal year 2023: -$17.07 million | Fiscal year 2022: -$109.91 million | Fiscal year 2021: -$58.87 million | Fiscal year 2020: -$21.13 million | Fiscal year 2019: -$16.85 million | Fiscal year 2018: -$19.70 million | Fiscal year 2017: -$20.13 million | Fiscal year 2016: -$21.70 million | Fiscal year 2015: -$7.63 million | Fiscal year 2014: -$6.35 million | Fiscal year 2013: -$52.4 thousand | Fiscal year 2012: -$56.4 thousand | Fiscal year 2011: -$133.6 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: